RN
Rabab Nasrallah
Investment Professional at Earlybird Venture Capital
RN
Rabab Nasrallah
Investment Professional at Earlybird Venture Capital
Germany
Overview
Rabab Nasrallah is a Principal at Earlybird Venture Capital in Germany, with a background in biochemistry, molecular biology, and cell culture. With experience in various research and strategy roles, Rabab has served on the boards of multiple biotech companies and is actively involved in investing in digital health and health IT startups at various stages.
Highlights of Rabab's career include serving on the boards of Grey Wolf Therapeutics and ImCheck Therapeutics, as well as holding positions at The George Institute for Global Health and The University of Manchester as a postdoctoral research scientist.
Work Experience
Investment Professional
2020 - Current
Board Observer
2024
Member Board of Directors
2023
Board Observer
2022
Board Observer
2020
Research Engagement
2020 - 2020
Program Manager
2019 - 2020
Design programmes that can support startup founders in developing their business models. Establishing new relationships with research communities to shape the future growth phase of INCUBATE. Identify and engage key stakeholders within new ecosystems to support INCUBATE's growth agenda.
Strategy Research Associate
2019 - 2020
Babraham Institute Knowledge Exchange and Commercialisation committee member
2018 - 2019
Reviewing funding applications to support translational innovation projects.
Postdoctoral Research Scientist
2016 - 2019
Commercialisation and market research for Medical i-Teams Cambridge
2017 - 2018
Investigating the commercial potential and landscape of emerging medical technologies.
Postdoctoral Research Scientist, CRUK Manchester
2014 - 2014
Stem cell biology research in the Lab of Dr. Georges Lacaud, Valerie kouskoff, and John Pimanda